Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response

AIDS Research and Human Retroviruses

Volumn 15, Issue 6, 1999, Pages 561-570

  Quinnan Jr , Gerald V ^a   Zhang, Peng Fei ^a   Fu, Da Wei ^a,b   Dong, Ming ^a   Alter, Harvey J ^c   Mascola, J ^d   Allen, S ^e   Ellner, J ^f   Nelson, K ^f   Sheppard, H ^f   Francis, G ^g  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b National Vaccine and Serum Institute   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d US Military HIV Research Program   (United States)

^e HIVNET Investigators   (United States)

^f Berkeley CA ^*  (United States)

^g UNAIDS Program   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID COMPOSITION; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEROLOGY; TARGET CELL; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; GENOTYPE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHENOTYPE;

EID: 2442731886     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311088     Document Type: Article

References (49)

1. Luciw PA. In: Fields Virology (Fields BN, Knipe DM, and Howley PM, eds.), 3rd Ed. Lippincott-Raven, Philadelphia, 1996, pp. 1881-1952.
2. Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, and Sodroski J: Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992; 66:5635-5641.
3. Zwart G, Langedijk H, Van der Hoek L, de Jong JJ, Wolfs TF, Ramautarsing C, Bakker M, De Ronde A, and Goudsmit J: Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 1991;181:481-489.
4. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon S-W, Fung MS, Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, and Sodroski J: Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
5. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivassan K, Sodroski J, Moore JP, and Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type 1. J Virol 1996;70: 1100-1108.
6. Muster T, Stein F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
7. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, and Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4. J Virol 1993;67:3978-3988.
8. Cotropia J, Ugen KE, Kliks S, Broliden K, Broliden PA, Hoxie JA, Srikantan V, Williams WV, and Weiner DB: A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:221-232.
9. Sabri F, Chiodi F, and Fenyö EM: Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates. AIDS Res Hum Retroviruses 1996;12: 855-858.
10. Thali M, Charles M, Furman C, Cavacini L, Posner M, Robinson J, and Sodroski J: Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol 1994; 68:674-680.
11. Back NKT, Smit L, Schutten M, Nara PL, Tersmette M, and Goudsmit J: Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol 1993;67:6897-6902.
12. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, and Zolla-Pazner S: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997;9:1281-1290.
13. VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, and Birx DL: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997; 71:4319-4330.
14. Vujcic LK and Quinnan GV Jr: Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 1995;11:783-787.
15. D'Souza MP, Durda P, Hanson CV, Milman G, and collaborating investigators: Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: An international collaboration. AIDS 1991;5:1061-1070.
16. Quinnan G, Zhang P, Fu D, Dong M, and Margolick J: Evolution of neutralizing antibody response against HIV-1 virions and pseudovirions in Multicenter AIDS Cohort Study participants. AIDS Res Hum Retroviruses 1998;14:939-949.
17. Barnes WM: The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene 1992;112:29-35.
18. Cariello NF, Swenberg JA, and Skopek TR: Fidelity of Thermococcus litoralis DNA polymerase (Vent) in PCR determined by denaturing gradient gel electrophoresis. Nucleic Acids Res 1991; 19:4193-4198.
19. Stuve LL, Brown-Shimer S, Pachl C, Naharian R, Diaz D, and Burke RL: Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J Virol 1987;61:326-335.
20. Gao F, Yue L, Craig S, Thornton CL, Robertson DL, McCutchan FE, Bradac JA, Sharp PM, and Hahn BH: Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: Generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1359-1368.
21. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59:284-291.
22. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, and Peden KW: Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 1996;12:191-194.
23. Englund G, Theodore TS, Freed EO, Engleman A, and Martin MA: Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol 1995;69:3216-3219.
24. Seth A, Hodge DR, Thompson DM, Robinson L, Panayiotakis A, Watson DK, and Papas TS: ETS family proteins activate transcription from HIV-1 long terminal repeat. AIDS Res Hum Retroviruses 1993;9:1017-1023.
25. Mann DL, O'Brien SJ, Gilbert DA, Reid Y, Popovic M, Read-Connole E, Gallo RC, and Gazdar AF: Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses 1989;5:253-255.
26. Daniel MD, Li Y, Naidu YM, Durda PJ, Schmidt DK, Troup CD, Silva DP, MacKey JJ, Kestler HW III, Sehgal PK, King NW, Ohta Y, Hayami M, and Desrosiers RC: Simian immunodeficiency virus from African green monkeys. J Virol 1988;62:4123-4128.
27. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NL: Identification of a major co-receptor for primary isolates of HIV. Nature (London) 1996; 381:661-666.
28. Landau NR and Littman DR: Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 1992;66:5110-5113.
29. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, and Reitz MS Jr: Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995; 69:3712-3720.
30. Liou HC, Sha WC, Scott ML, and Baltimore D: Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-5359.
31. Mascola J, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, and Burke DS: Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
32. Park EJ, Vujcic LJ, Anand R, Theodore TS, and Quinnan GV: Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant HIV-1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 1998;72:7099-7107.
33. Lennette EH: General principles underlying laboratory diagnosis of viral and rickettsial infections. In: Diagnostic Procedures of Viral and Rickettsial Disease (Lennette EH and Schmidt MJ, eds.). American Public Health Association, New York, 1964, p. 45.
34. Higgins DG and Sharp PM: Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl Biosci 1989; 5:151-153.
35. Myers G, Berzofsky JA, Korber B, Smith RF, and Pavlakis GN: Human Retroviruses and AIDS 1992. Los Alamos National Laboratory, Los Alamos, New Mexico, 1993.
36. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4:406-425.
37. Myers EW and Miller W: Optimal alignments in linear space. Comput Appl Biosci 1988;4:11-17.
38. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, and Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60-67.
39. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
40. Fortin JF, Cantin R, and Tremblay MJ: T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM. J Virol 1998;72:2105-2112.
41. Zolla-Pazner S and Sharpe S: A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDs Res Hum Retroviruses 1995;11:1449-1458.
42. Porter KR, Mascola JR, Hupudio H, Ewing D, VanCott TC, Anthony RL, Convin AL, Widodo S, Ertono S, McCutchan FE, Burke DS, Hayes CG, Wignall FS, and Graham RR: Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:1-6.
43. Schonning K, Jansson B, Olofsson S, Nielsen JO, and Hansen JS: Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 1996;218:134-140.
44. Overbaugh J and Rudensey LM: Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J Virol 1992; 66:5937-5948.
45. Chackerian B, Rudensey LM, and Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997; 71:7719-7727.
46. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-444.
47. Korber BT, MacInnes K, Smith RF, and Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994;68:6730-6744.
48. Plantier JC, Le Pogam S, Poisson F, Buzelay L, Lejeune B, and Barin F: Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J Virol 1998;72: 677-683.
49. Ghiara JB, Stura EA, Stanfield RL, Profy AT, and Wilson IA: Crystal structure of the principal neutralization site of HIV. Science 1994;264:82-85.